Miravirsen (SPC-3649) is a potent miR-122 inhibitor and inhibits the biogenesis of miR-122. Miravirsen is a 15-nucleotide locked nucleic acid-modified phosphorothioate antisense oligonucleotide. Miravirsen inhibits HCV replication. Miravirsen can be used in research of HCV infection In Vitro Miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122. Miravirsen binds to the stem-loop structure of pri- and pre-miR-122 with nanomolar affinity, and inhibits both Dicer- and Drosha-mediated processing of miR-122 precursors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Miravirsen (SPC-3649; 2.5-25 mg/kg; i.v.; daily, for 3 d) inhibits miR-122 activity in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NMRI female mice (27 g)Dosage: 2.5, 6.25, 12.5, and 25 mg/kg Administration: Intravenous injection; daily, for 3 days Result: Inhibited miR-122 activity in a dose-dependent manner. Form:Solid IC50& Target:miR-122